Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

Trial Profile

Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Olaparib (Primary) ; Temozolomide (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Feb 2017 Status changed to recruiting.
    • 05 Jan 2017 Planned number of patients changed from 38 to 29.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top